Return on Equity (ROE)

Amgen's current Return on Equity (ROE) of 89.1% means that for every dollar of shareholders' equity, the company generated 89.1 cents in profit over the past year — a measure of how efficiently it uses investor capital.

This figure far exceeds the healthcare sector median of 11.1%, placing Amgen at the 95th percentile among its sector peers, indicating exceptional profitability relative to competitors. The trend direction is not available: the year-over-year change is marked as N/A, the quarter-over-quarter change as N/A, and the historical values show only the single current figure of 89.1% with no prior data. Without any trend information, it is impossible to assess whether this high ROE is stable, improving, or declining, which adds uncertainty to the investment outlook. The combination of an extremely high ROE level with no trend data suggests that while the current profitability is an opportunity, the lack of momentum creates risk for investors relying on consistency. This metric supports the overall NEUTRAL verdict because the outstanding ROE is a positive signal, but the absence of trend data prevents a stronger bullish or bearish stance — the stock warrants further investigation before action.

Frequently Asked Questions

Closest Sector Peers